Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic hepatitis C infection for at least 6 months duration
Hepatitis C genotype 1a or 1b
Participants must have discontinued prior hepatitis C treatment at least 12 weeks prior to enrollment in this study
Participants showed a previous null response to therapy as defined by \< 2 logarithm to the base 10 (log10) international units per milliliter (IU/mL) decrease in viral titer after at least 12 weeks of treatment with PEG-IFN/RBV
You may not be if
Hepatitis C infection with a genotype other than genotype 1a or 1b
Body mass index \< 18 or \>= 36 kilograms per square meters (kg/m\^2)
Hepatitis A, hepatitis B, or human immunodeficiency virus (HIV) infection
Herbal remedies \<=1 month prior to the first dose of study drug
Clareo Health | A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C
